FR14C0010I2 - Utilisation de l'acide (z)-2-cyano-3-hydroxy-but-2-enoique-(4'-trifluoromethylphenyl)-amide pour le traitement de la sclerose en plaques - Google Patents
Utilisation de l'acide (z)-2-cyano-3-hydroxy-but-2-enoique-(4'-trifluoromethylphenyl)-amide pour le traitement de la sclerose en plaquesInfo
- Publication number
- FR14C0010I2 FR14C0010I2 FR14C0010C FR14C0010C FR14C0010I2 FR 14C0010 I2 FR14C0010 I2 FR 14C0010I2 FR 14C0010 C FR14C0010 C FR 14C0010C FR 14C0010 C FR14C0010 C FR 14C0010C FR 14C0010 I2 FR14C0010 I2 FR 14C0010I2
- Authority
- FR
- France
- Prior art keywords
- enoic
- trifluoromethylphenyl
- cyano
- hydroxy
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000002253 acid Substances 0.000 title 1
- 201000006417 multiple sclerosis Diseases 0.000 title 1
- UTNUDOFZCWSZMS-YFHOEESVSA-N teriflunomide Chemical compound C\C(O)=C(/C#N)C(=O)NC1=CC=C(C(F)(F)F)C=C1 UTNUDOFZCWSZMS-YFHOEESVSA-N 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/215—IFN-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28168501P | 2001-04-05 | 2001-04-05 | |
| GBGB0123571.2A GB0123571D0 (en) | 2001-04-05 | 2001-10-02 | Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating multiple sclerosis |
| PCT/US2002/010773 WO2002080897A1 (en) | 2001-04-05 | 2002-04-04 | Use of (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating multiple sclerosis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FR14C0010I1 FR14C0010I1 (enrdf_load_stackoverflow) | 2014-03-14 |
| FR14C0010I2 true FR14C0010I2 (fr) | 2014-11-21 |
Family
ID=26246599
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR14C0010C Active FR14C0010I2 (fr) | 2001-04-05 | 2014-02-05 | Utilisation de l'acide (z)-2-cyano-3-hydroxy-but-2-enoique-(4'-trifluoromethylphenyl)-amide pour le traitement de la sclerose en plaques |
Country Status (15)
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003293500A1 (en) | 2002-12-12 | 2004-07-09 | Agennix Incorporated | Lactoferrin in the reduction of pain |
| SG142305A1 (en) * | 2004-10-19 | 2008-05-28 | Aventis Pharma Inc | Use of (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'- trifluoromethylphenyl)-amide for treating inflammatory bowel disease |
| AU2005318163B2 (en) | 2004-12-21 | 2011-12-01 | Merck Serono Sa | Sulfonyl amino cyclic derivatives and use thereof |
| SI1844032T1 (sl) | 2005-01-31 | 2011-09-30 | Merck Serono Sa | Derivati n-hidroksiamida in njihova uporaba |
| CA2616479A1 (en) | 2005-09-01 | 2007-03-08 | Ares Trading S.A. | Treatment of optic neuritis |
| ES2319596B1 (es) | 2006-12-22 | 2010-02-08 | Laboratorios Almirall S.A. | Nuevos derivados de los acidos amino-nicotinico y amino-isonicotinico. |
| UY31272A1 (es) | 2007-08-10 | 2009-01-30 | Almirall Lab | Nuevos derivados de ácido azabifenilaminobenzoico |
| EP2100881A1 (en) | 2008-03-13 | 2009-09-16 | Laboratorios Almirall, S.A. | Pyrimidyl- or pyridinylaminobenzoic acid derivatives |
| EP2135610A1 (en) | 2008-06-20 | 2009-12-23 | Laboratorios Almirall, S.A. | Combination comprising DHODH inhibitors and methotrexate |
| EP2239256A1 (en) | 2009-03-13 | 2010-10-13 | Almirall, S.A. | Sodium salt of 5-cyclopropyl-2-{[2-(2,6-difluorophenyl)pyrimidin-5-yl]amino}benzoic acid as DHODH inhibitor |
| EP2228367A1 (en) | 2009-03-13 | 2010-09-15 | Almirall, S.A. | Addition salts of amines containing hydroxyl and/or carboxylic groups with amino nicotinic acid derivatives as DHODH inhibitors |
| EP2230232A1 (en) | 2009-03-13 | 2010-09-22 | Almirall, S.A. | Addition salts of tromethamine with azabiphenylaminobenzoic acid derivatives as DHODH inhibitors |
| EP2277515A1 (en) * | 2009-07-10 | 2011-01-26 | Sanofi-Aventis | Use of the combination of teriflunomide and interferon beta for treating multiple sclerosis |
| US20120172427A1 (en) * | 2009-09-18 | 2012-07-05 | Sanofi | (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide tablet formulations with improved stability |
| EP2314577A1 (en) | 2009-10-16 | 2011-04-27 | Almirall, S.A. | Process for manufacturing 2-[(3,5-difluoro-3'-methoxy-1,1'-biphenyl-4-yl)amino]nicotinic acid |
| US8686048B2 (en) | 2010-05-06 | 2014-04-01 | Rhizen Pharmaceuticals Sa | Immunomodulator and anti-inflammatory compounds |
| WO2012109329A2 (en) | 2011-02-08 | 2012-08-16 | Children's Medical Center Corporation | Methods for treatment of melanoma |
| EP2762135A1 (en) * | 2013-02-04 | 2014-08-06 | Sanofi | Methods for reducing the risk of an adverse teriflunomide and rosuvastatin interaction in multiple sclerosis patients |
| WO2016189406A1 (en) | 2015-05-23 | 2016-12-01 | Ftf Pharma Private Limited | Pharmaceutical composition of teriflunomide |
| JOP20190207A1 (ar) | 2017-03-14 | 2019-09-10 | Actelion Pharmaceuticals Ltd | تركيبة صيدلانية تشتمل على بونيسيمود |
| GR1010137B (el) | 2020-12-15 | 2021-12-07 | Φαρματεν Α.Β.Ε.Ε., | Στερεη φαρμακοτεχνικη μορφη αμεσης αποδεσμευσης περιεχουσα τεριφλουνομιδη και μεθοδος παρασκευης αυτης |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES448386A1 (es) | 1975-06-05 | 1978-04-16 | Hoechst Ag | Procedimiento para la preparacion de anilidas de acido 5-me-til-isoxazol-4-carboxilico. |
| DE2854439A1 (de) | 1978-12-16 | 1980-07-03 | Hoechst Ag | Ein isoxazolderivat, verfahren zu seiner herstellung, diese verbindung enthaltende mittel und verwendung |
| US5268382A (en) | 1985-09-27 | 1993-12-07 | Hoechst Aktiengesellschaft | Medicaments to combat autoimmune diseases, in particular systemic lupus erythematosus |
| DE3534440A1 (de) | 1985-09-27 | 1987-04-02 | Hoechst Ag | Arzneimittel gegen chronische graft-versus-host-krankheiten sowie gegen autoimmunerkrankungen, insbesondere systemischen lupus erythematodes |
| TW314467B (enrdf_load_stackoverflow) | 1993-03-31 | 1997-09-01 | Hoechst Ag | |
| US5700823A (en) | 1994-01-07 | 1997-12-23 | Sugen, Inc. | Treatment of platelet derived growth factor related disorders such as cancers |
| DE19547648A1 (de) * | 1995-12-20 | 1997-06-26 | Hoechst Ag | Zubereitung, enthaltend High Density Lipoproteine und Crotonsäureamidderivate |
-
2002
- 2002-04-04 CA CA002443285A patent/CA2443285C/en not_active Expired - Fee Related
- 2002-04-04 ES ES02763962T patent/ES2305287T3/es not_active Expired - Lifetime
- 2002-04-04 EP EP08004647A patent/EP1935416A3/en not_active Ceased
- 2002-04-04 SI SI200230727T patent/SI1381356T1/sl unknown
- 2002-04-04 AT AT02763962T patent/ATE396719T1/de active
- 2002-04-04 PT PT02763962T patent/PT1381356E/pt unknown
- 2002-04-04 DE DE60226855T patent/DE60226855D1/de not_active Expired - Lifetime
- 2002-04-04 DK DK02763962T patent/DK1381356T3/da active
- 2002-04-04 EP EP02763962A patent/EP1381356B1/en not_active Expired - Lifetime
- 2002-04-04 WO PCT/US2002/010773 patent/WO2002080897A1/en not_active Application Discontinuation
- 2002-04-04 AR ARP020101245A patent/AR033459A1/es not_active Application Discontinuation
- 2002-04-05 PA PA20028542901A patent/PA8542901A1/es unknown
- 2002-04-05 UY UY27244A patent/UY27244A1/es unknown
-
2014
- 2014-01-23 CY CY2014004C patent/CY2014004I2/el unknown
- 2014-01-29 LU LU92366C patent/LU92366I2/fr unknown
- 2014-02-05 FR FR14C0010C patent/FR14C0010I2/fr active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP1935416A2 (en) | 2008-06-25 |
| EP1935416A3 (en) | 2008-10-22 |
| FR14C0010I1 (enrdf_load_stackoverflow) | 2014-03-14 |
| DK1381356T3 (da) | 2008-09-22 |
| CA2443285C (en) | 2007-08-21 |
| WO2002080897A1 (en) | 2002-10-17 |
| LU92366I2 (fr) | 2014-03-31 |
| PT1381356E (pt) | 2008-07-24 |
| UY27244A1 (es) | 2002-07-31 |
| EP1381356A1 (en) | 2004-01-21 |
| ES2305287T3 (es) | 2008-11-01 |
| DE60226855D1 (de) | 2008-07-10 |
| PA8542901A1 (es) | 2003-11-12 |
| SI1381356T1 (sl) | 2008-12-31 |
| EP1381356B1 (en) | 2008-05-28 |
| CY2014004I1 (el) | 2015-12-09 |
| AR033459A1 (es) | 2003-12-17 |
| CY2014004I2 (el) | 2015-12-09 |
| ATE396719T1 (de) | 2008-06-15 |
| CA2443285A1 (en) | 2002-10-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FR14C0010I2 (fr) | Utilisation de l'acide (z)-2-cyano-3-hydroxy-but-2-enoique-(4'-trifluoromethylphenyl)-amide pour le traitement de la sclerose en plaques | |
| EP1390029A4 (en) | PHENYLINDOLE FOR THE TREATMENT OF HIV | |
| FR2843295B1 (fr) | Instrument pour le traitement de fracture de tassement de corps vertebraux | |
| FR2854074B1 (fr) | Utilisation de l'ivermectine pour le traitement de desordres dermatologiques | |
| FR2846870B1 (fr) | Materiel d'osteosynthese pour le traitement d'un cubitus"long" | |
| FR07C0046I2 (fr) | Beta-l-2'-desoxy-nucleosides pour le traitement de l'hepatite b | |
| EP1392844A4 (en) | Use of hmg fragments as anti-inflammatory agents | |
| ITMI20022234A1 (it) | Apparecchiatura e procedimento per l'esecuzione di codifica | |
| EP1438062A4 (en) | METHOD AND COMPOSITIONS FOR TREATING SKIN Lions | |
| EP1369422A4 (en) | METHOD FOR PRODUCING ALKENYLPHOSPHINOXIDES OR ALKENYLPHOSPHINIC ACID ESTERS | |
| EP1424946A4 (en) | BONE PLATES | |
| ITMI20012052A0 (it) | Procedimento per la capitazione e l'abbattimento delle polveri volatili | |
| GB0123571D0 (en) | Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating multiple sclerosis | |
| MA26289A1 (fr) | Faible concentration de peroxyde pour le traitement ou la prevention d'infections vaginales | |
| FR2841470B1 (fr) | Utilisation d'isoflavones pour la preparation de compositions topiques utiles pour favoriser l'amincissement et methode de traitement cosmetique associee | |
| MA24332A1 (fr) | Utilisation de 1-hydroxy-2- pyridones pour le traitement d'infections de la peau | |
| IL157176A0 (en) | Purification of 2-nitro-4-methylsulphonylbenzoic acid | |
| FR2800614B1 (fr) | Composition pour le traitement des infections des voies respiratoires | |
| FR2829134B1 (fr) | Procede de preparation de (meth) acrylates d'alkylimidazolidone | |
| FR2810547B1 (fr) | Utilisation d'acides en c2-c10 pour la prevention des infections a bacteries a gram negatif | |
| MA26117A1 (fr) | Nouveau compose pour le traitement de l'impuissance | |
| NO20025964L (no) | Ny interferon for behandling av multippel sklerose | |
| FR2837101B1 (fr) | Utilisation de l'acide 6-[1-adamantyl)-4-methoxyphenyl]-2- naphthoique pour le traitement de desordres dermatologiques | |
| MA25852A1 (fr) | Methode pour le traitement de l'inflammation. | |
| FR2822308B1 (fr) | Circuit pour la separation de poles reposant sur l'effet miller |